Posts by: Iqra Mumal, MSc

Iqra Mumal, MSc

Iqra holds a MSc in Cellular and Molecular Medicine from the University of Ottawa in Ottawa, Canada. She also holds a BSc in Life Sciences from Queen’s University in Kingston, Canada. Currently, she is completing a PhD in Laboratory Medicine and Pathobiology from the University of Toronto in Toronto, Canada. Her research has ranged from across various disease areas including Alzheimer’s disease, myelodysplastic syndrome, bleeding disorders and rare pediatric brain tumors.

July 9, 2018July 9, 2018

Innovate Partnering with University of Maryland to Investigate Larazotide’s Potential to Treat IBD

News

Innovate Biopharmaceuticals Inc. will collaborate with a researcher at the University of Maryland School of Medicine to develop larazotide as a potential treatment for diseases that affect the intestinal barrier, ... Read more

June 25, 2018June 25, 2018

International GEM Project Studying Crohn’s Disease Reaches Goal of 5,000 Participants

News

The Genetic, Environmental, Microbial (GEM) Project — the world’s largest clinical study investigating the causes of Crohn’s disease — has reached its goal of recruiting 5,000 participants, Crohn’s and Colitis Canada recently announced. ... Read more

June 6, 2018June 6, 2018

Eisai’s Small Molecule Analog Reduced Inflammation and Injury in Mice with IBD, Study Shows

News

A small molecule analog developed by Eisai, called ER-464195-01, may be a potential therapy for patients with inflammatory bowel disease (IBD) by reducing infiltration of inflammatory cells, according to researchers. Their ... Read more

June 4, 2018June 4, 2018

Patients with IBD More Likely to Develop Parkinson’s Disease, Study Suggests

News

Patients with inflammatory bowel disease (IBD) have a 22% higher risk of developing Parkinson’s disease, a large-scale observational study suggests. The study, “Inflammatory bowel disease increases the risk of Parkinson’s ... Read more

May 14, 2018May 14, 2018

OSE Immunotherapeutics Presents Promising New Data on OSE-127’s Potential to Treat IBD

News

OSE Immunotherapeutics presented new preclinical results on its investigational therapy candidate OSE-127, further validating its potential for the treatment of inflammatory bowel diseases (IBD). Results were presented in an abstract titled, ... Read more

May 4, 2018May 4, 2018

Immunic Starts Enrollment in Phase 2 CALDOSE-1 Clinical Trial

News

The first patient has enrolled in the CALDOSE-1 phase 2 clinical trial, which seeks to determine whether Immunic AG‘s investigational drug IMU-838 can induce and maintain remission in patients with active ... Read more

March 6, 2018March 6, 2018

Signaling from Nervous System Helped Control Inflammatory Response in IBD, Mouse Study Shows

News

Signaling from the nervous system through the β2-adrenergic receptor can help control the type of inflammation that characterizes inflammatory bowel disease (IBD), a new mouse study shows. These findings suggest ... Read more

February 26, 2018

IBD Patients with Iron Deficiency Treated Intravenously Had More Clinical, Cost Benefits, Study Finds

News

Researchers found that patients with inflammatory bowel disease (IBD) with iron deficiency (ID) or iron deficiency anemia (IDA) who were administered iron intravenously were hospitalized less frequently and had lower ... Read more

February 16, 2018

Migration and Race May Play a Role in the Development of IBD

News

A recent review suggests that migration and race influence the risk of developing inflammatory bowel disease. In particular, South Asian migrants have a consistently higher incidence of ulcerative colitis and ... Read more

February 5, 2018February 5, 2018

Kenneth Rainin Foundation Gives $1.7M in ‘Synergy Awards’ for IBD Research

News

The Kenneth Rainin Foundation has given $1.7 million in prize money to support collaborative research into preventing and detecting inflammatory bowel disease (IBD). The Synergy Awards are aimed at getting experts ... Read more